When a new therapy, funded by The Leukemia & Lymphoma Society (LLS), receives Food and Drug Administration (FDA) approval with a "breakthrough therapy designation," it signals the kind of progress that represents our goal for patients since our founding 65 years ago - new, effective treatments.
That's why we're pleased to announce FDA approval of ibrutinib (Imbruvica™), the LLS-funded therapy for the treatment of chronic lymphocytic leukemia (CLL). This easy-to-take pill - that targets the cancer - may allow CLL patients to avoid the adverse effects of standard chemotherapy. John C. Byrd, MD, of the Ohio State University, is a world-renowned CLL expert who leads the LLS-funded team that has been instrumental in advancing ibrutinib for CLL and credits LLS funding for making this FDA approval possible.
This past November the FDA also approved ibrutinib to treat patients with mantle cell lymphoma, and it is proving to be a significant advance for patients with this blood cancer.
LLS depends on funding from people like you who want to make a difference in the lives of people with blood cancer. Ibrutinib is proof of how your support helps advance new therapies that save more lives not someday, but today. Read the full story about ibrutinib.
No comments:
Post a Comment